FDA rejects two China-developed cancer drugs
Bio Pharma Dive
MAY 2, 2022
The regulator cited concerns around single-country trials in turning back Hutchmed's pancreatic cancer treatment, while manufacturing issues held up Junshi and Coherus' throat cancer medicine
Let's personalize your content